All In Biotech

Investigational drug · Phase 3

Obrixtamig

Also called: BI 764532

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

6 still active

All registered trials

14

Any phase or sponsor naming "Obrixtamig"

First trial start

2023

Oct 13, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Obrixtamig", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Small Cell Lung Cancer
  • Large Cell Neuroendocrine Lung Carcinoma
  • Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
  • Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
  • Small Cell Lung Carcinoma
  • Neuroendocrine Neoplasms
  • Extra-pulmonary Neuroendocrine Carcinoma
  • Advanced Cancer
  • Small Cell Lung Cancer (SCLC)
  • Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Approved drugs for the same conditions: Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Obrixtamig" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for Small Cell Lung Cancer

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • I-DXdDS-7300a, MK-2400Phase 317 trials

    Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma

  • SYS6010Phase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials

    MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer

  • ZG005Phase 311 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer

  • ZG006Phase 38 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor

  • ABBV-706Phase 34 trials

    AbbVie · Small Cell Lung Cancer, Extensive Stage-Small Cell Lung Cancer (ES-SCLC), Extensive Stage-Small Cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.